Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy

被引:39
作者
Goodman, WG
Jüppner, H
Salusky, IB
Sherrard, DJ
机构
[1] Univ Calif Los Angeles, Med Ctr, Div Nephrol, Sch Med,Dept Med, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Sch Med, Dept Pediat, Div Pediat Nephrol, Los Angeles, CA 90024 USA
[3] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA
[4] Vet Adm Puget Sound Hlth Care Syst, Seattle, WA USA
关键词
immunometric PTH assay; clinical management; end-stage renal disease; peptides and bone cells; chronic renal failure; skeletal lesions; PTH(1-84); renal bone disease;
D O I
10.1046/j.1523-1755.2003.00700.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Reliable measurements of parathyroid hormone (PTH) concentrations in serum or plasma are critical for the appropriate diagnosis and management of patients with renal osteodystrophy. With the introduction of second generation immunometric assays for PTH, it is now possible to measure exclusively full-length, biologically active PTH(1-84). In contrast, first generation immunometric assays that have been used widely for many years detect not only PTH(1-84), but also other large amino-terminally-truncated, PTH-derived peptides. This development will require a careful re-evaluation of PTH measurements, as determined by either first or second generation immunometric assays, and their relationship to bone histology and bone remodeling rates in patients with end-stage renal disease (ESRD). Such information is essential for proper clinical management, but only limited bone biopsy data are available to guide the interpretation of PTH results using second generation PTH assays. The different performance characteristics of first and second generation immunometic PTH assays also makes it possible to quantify the plasma levels of amino-terminally-truncated, PTH-derived peptides, which may accumulate disproportionately in patients with ESRD. Recent experimental evidence indicates that one or more of these peptides can modify bone cell activity and skeletal remodeling, possibly by interacting with a PTH receptor distinct from the type I PTH receptor that binds to the amino-terminal portion of PTH and mediates the classical biological actions of the hormone. The putative C-PTH receptor interacts with mid- and/or carboxyterminal regions of PTH and other amino-terminally-truncated PTH-derived peptides; signaling through it may contribute to the skeletal resistance to PTH that characterizes ESRD. The current review discusses certain aspects of the molecular structure of PTH and its interaction with various receptors, briefly comments about selected components of PTH secretion, highlights recent technical advances in PTH assays, and summarizes the effects of various PTH-derived peptides on bone cells and on skeletal metabolism.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 79 条
[31]   Megalin antagonizes activation of the parathyroid hormone receptor [J].
Hilpert, J ;
Nykjaer, A ;
Jacobsen, C ;
Wallukat, G ;
Nielsen, R ;
Moestrup, SK ;
Haller, H ;
Luft, FC ;
Christensen, EI ;
Willnow, TE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (09) :5620-5625
[32]  
Hoare SRJ, 2000, J PHARMACOL EXP THER, V295, P761
[33]   Comparison of rat and human parathyroid hormone 2 (PTH2) receptor activation: PTH is a low potency partial agonist at the rat PTH2 receptor [J].
Hoare, SRJ ;
Bonner, TI ;
Usdin, TB .
ENDOCRINOLOGY, 1999, 140 (10) :4419-4425
[34]   Evaluating the ligand specificity of zebrafish parathyroid hormone (PTH) receptors:: Comparison of PTH, PTH-related protein, and tuberoinfundibular peptide of 39 residues [J].
Hoare, SRJ ;
Rubin, DA ;
Jüppner, H ;
Usdin, TB .
ENDOCRINOLOGY, 2000, 141 (09) :3080-3086
[35]   CORRECTION OF ABNORMAL BONE AND MINERAL METABOLISM IN CHRONIC STREPTOZOTOCIN-INDUCED DIABETES-MELLITUS IN THE RAT BY INSULIN THERAPY [J].
HOUGH, S ;
AVIOLI, LV ;
BERGFELD, MA ;
FALLON, MD ;
SLATOPOLSKY, E ;
TEITELBAUM, SL .
ENDOCRINOLOGY, 1981, 108 (06) :2228-2234
[36]   CORRELATION OF BONE-HISTOLOGY WITH PARATHYROID-HORMONE, VITAMIN-D3, AND RADIOLOGY IN END-STAGE RENAL-DISEASE [J].
HUTCHISON, AJ ;
WHITEHOUSE, RW ;
BOULTON, HF ;
ADAMS, JE ;
MAWER, EB ;
FREEMONT, TJ ;
GOKAL, R .
KIDNEY INTERNATIONAL, 1993, 44 (05) :1071-1077
[37]   CHARACTERIZATION OF A NOVEL PARATHYROID-HORMONE (PTH) RECEPTOR WITH SPECIFICITY FOR THE CARBOXYL-TERMINAL REGION OF PTH-(1-84) [J].
INOMATA, N ;
AKIYAMA, M ;
KUBOTA, N ;
JUPPNER, H .
ENDOCRINOLOGY, 1995, 136 (11) :4732-4740
[38]   A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments:: Implications for PTH measurements in renal failure [J].
John, MR ;
Goodman, WG ;
Gao, P ;
Cantor, TL ;
Salusky, IB ;
Jüppner, H .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (11) :4287-4290
[39]   Identification and characterization of the murine and human gene encoding the tuberoinfundibular peptide of 39 residues [J].
John, MR ;
Arai, M ;
Rubin, DA ;
Jonsson, KB ;
Jüppner, H .
ENDOCRINOLOGY, 2002, 143 (03) :1047-1057
[40]   Tuberoinfundibular peptide 39 binds to the parathyroid hormone (PTH)/PTH-related peptide receptor, but functions as an antagonist [J].
Jonsson, KB ;
John, MR ;
Gensure, RC ;
Gardella, TJ ;
Jüppner, H .
ENDOCRINOLOGY, 2001, 142 (02) :704-709